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Background: ATS/ERS Task Force has highlighted that special attention must be paid when FEV1 and FVC are
concomitantly decreased (<5th percentile) and the FEV1/FVC ratio is normal (>5
th percentile) because a possible
cause of this non specific pattern (NSP) is collapse of small airways with normal TLC measured by body
plethysmography (>5th percentile). Our objectives were to determine the main lung diseases associated with this
pattern recorded prospectively in a lung function testing (LFT) unit, the prevalence of this pattern in our LFT and
among the diseases identified, and its development.
Methods: Observational study of routinely collected data selected from our Clinical Database Warehouse.
Results: The prevalence of NSP was 841/12 775 tests (6.6%, 95% CI: 6.2 to 7.0%). NSP was mainly associated with
seven lung diseases: asthma (prevalence of NSP among asthmatics: 12.6%), COPD/emphysema (prevalence 8.6%),
bronchiectasis (12.8%), sarcoidosis (10.7%), interstitial pneumonia (4.0%), pulmonary hypertension (8.9%) and
bilateral lung transplantation for cystic fibrosis (36.0%). LFT measurements were described in 185 patients with NSP
and indisputable nonoverlapping causes. A moderate defect (FEV1: 66 ± 9% predicted) with mild lung hyperinflation
(FRC: 111 ± 27%, RV: 131 ± 33% predicted: suggesting distal airway obstruction) was evidenced whatever the
underlying cause. A long term stability of NSP was evidenced in 130/185 patients (70% 95% CI: 64 to 77%).
Conclusions: NSP is observed in asthma, COPD/emphysema, bronchiectasis, sarcoidosis, pulmonary hypertension,
interstitial pneumonia and after bilateral lung transplantation and remains stable in the majority of patients.
Keywords: Asthma, Bronchiectasis, COPD, Emphysema, Pulmonary hypertension, Sarcoidosis, Small airway
obstructive syndrome, Non specific pattern of lung functionBackground
An obstructive ventilatory defect is a disproportionate re-
duction in maximal airflow from the lung in relation to
the maximal volume (i.e. vital capacity, VC) that can be
displaced from the lung [1]. It is defined by a reduced
Forced Expiratory Volume in 1 second (FEV1)/VC ratio
below the 5th percentile of the predicted value. As stated* Correspondence: christophe.delclaux@egp.aphp.fr
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article, unless otherwise stated.by the ATS/ERS task force [1], “special attention must be
paid when FEV1 and forced VC (FVC) are concomitantly
decreased and the FEV1/FVC ratio is normal or almost
normal […]. A possible cause of this pattern is patchy col-
lapse of small airways early in exhalation. Under these
conditions, total lung capacity (TLC) may be normal, but
residual volume (RV) is ordinarily increased. ” This pat-
tern has been named as small airways obstruction syn-
drome by Stanescu [2], and has initially been described in
small series of adults with emphysema, small airways dis-
eases, bronchial asthma [2] and also in asthmatic children
[3]. Hyatt and colleagues identified more recently thed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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database of lung function tests (LFT) results and med-
ical records [4]. These authors showed that 68% of the
patients were suffering from airway disease (including
asthma, chronic obstructive pulmonary disease [COPD]
and bronchiectasis), while the others suffered from re-
stricted expansion of the thorax or the lung [4]. Conse-
quently, they preferred to define this pattern as a non
specific pattern (NSP).
The objective of our observational study using rou-
tinely collected data were to confirm the results of Hyatt
and colleagues (main lung diseases associated with this
syndrome), to further assess the prevalence of this syn-
drome in these diseases and to describe the follow-up of
this NSP as done by the same research group [5]. These
objectives have practical consequences for lung function
testing units because if the prevalence of the syndrome
is “significant” it is a plea for systematic absolute lung
volume measurement when a reduction of FEV1 with a
normal FEV1/FVC ratio is evidenced.
Methods
Reporting is in accordance with STROBE Statement
(http://www.strobe-statement.org/). Unfortunately, the
statements of the REporting of studies Conducted using
Observational Routinely collected Data (RECORD,
http://www.strobe-statement.org/) are not available.
Design
Since January 2007, explicit procedures for the interpret-
ation of LFT using a standardised report based on inter-
pretative strategies of the ATS/ERS task force, including
NSP definition (FEV1 and FVC < 5
th percentile with FEV1/
FVC > 5th percentile and TLC measured by body plethys-
mography > 5th percentile [1]), have been implemented in
our unit. The physicians who are responsible for ordering
tests have to state the clinical question to be answered and
the physicians who are responsible for interpreting the re-
sults of LFT further ask patients why they were sent for
testing, record ethnicity (mandatory), respiratory symptoms
(including Medical Research Council [MRC] dyspnea score
1 to 5, mandatory), as well as smoking status (mandatory),
the type and dosage of any medication that may alter lung
function (tests are performed while the patient takes his/
her usual treatment excepting methacholine challenge test),
including when the drugs were last administered, and qual-
ity criteria of LFT in our database allowing a standardized
LFT report (mandatory: see Figure 1).
Our first objective was to identify the main lung dis-
eases associated with the recording of NSP. It has to be
stated that a non reduced TLC measured by body pleth-
ysmography was an inclusion criterion according to
guidelines [1]; thus patients with restricted expansion of
the lung and the chest wall were not retrieved even ifour clinical experience shows that some patients with inter-
stitial pneumonia may exhibit a more significant reduction
of FEV1 and FVC (as compared with TLC reduction) with
normal FEV1/FVC (complex restrictive pattern [6]).
Due to the observational design of the study using
routinely collected data only indisputable diagnoses
were selected by the agreement between the diagnosis
reported (1) by the LFT physician making the report
(LFT Database), and (2) by the code in the Clinical
Database Warehouse (CDW, including International
Classification of Diseases [ICD-10, recorded by the staff
of pulmonologists] and CCAM French public health in-
surance codes). Furthermore, the diagnoses were con-
trolled for tobacco exposure. We thus selected patients
(from January, 2007 to December, 2012) based on their
smoking history: COPD were smokers ≥ 15 pack-year
(repeated LFT allowed to ensure conventional criteria of
COPD, namely post-bronchodilator FEV1/FVC < 70%;
emphysema, especially centrilobular, was deemed to be
present in presence of associated hyperinflation [any in-
crease in static lung volumes]), while other diagnoses
were associated with a smoking history < 15 pack-year.
If the patient had undergone multiple LFT over this 6-
year period, we used only the measurements from their
first visit for the cross-sectional assessment. Obviously,
for COPD patients, NSP diagnosis is incompatible with
COPD diagnosis since FEV1/FVC is > 70%. Thus, only
COPD patients with transient NSP were retrieved [5].
Finally patients with multiple lung disease diagnoses
were excluded.
The second objective was to evaluate the prevalence
of the NSP in our LFT unit and among the main lung
diseases that have been identified, using the number of
NSP over all tests recorded in the LFT database and the
number of NSP in each lung disease over the number of
patients with each disease having had LFT, respectively.
The third objective was to assess the long term follow-
up of the patients exhibiting NSP.
The selection process is summarized in Figure 1, it sat-
isfied to the following steps:
1. For the main objective (main lung diseases
associated with NSP)
- extraction of all LFT recorded as NSP in the LFT
database
- selection of the first LFT for each patient with NSP
- identification of main lung diseases associated with
NSP (LFT database): recorded diagnosis for at least
5 patients (miscellaneous diseases were excluded, see
Figure 1 legend)
- confirmation of the diagnosis by pulmonologists
(ICD-10 database)
- selection of Caucasian subjects with NSP
- extraction of LFT raw data of patients with NSP
Figure 1 Selection of the patients and prevalence estimation. LFT: lung function tests; NSP: Non Specific Pattern; COPD: chronic obstructive
pulmonary disease; BLT: bilateral lung transplantation (that was identified in the Clinical Database Warehouse by a specific CCAM code). PY: Pack-years
for smoking history. The process of data selection is described in the Methods section. On the right side of the flow-chart diagram, the selection
process of the 185 patients with NSP described in Table 2 is showed. The first step allowed the selection of patients instead of LFT (from 841 LFT to
360 patients): 30 patients with miscellaneous diseases (see Methods) were excluded, and 360 patients were selected (451 tests were follow-up LFT). All
these 360 patients had the “NSP” diagnosis selected by the physician in charge of the medical report, based on the results of LFT showing the
predicted value of each parameter and their 5th percentile (95th percentile for absolute lung volumes, additionally) based on normative equations for
spirometry and lung volumes with correction for ethnicity [13,14]. Consequently, the prevalence of NSP in each lung disease was calculated from this
sample. The next step was conducted to describe lung function test results from a highly selected subgroup with indisputable diagnoses. For the
purpose of the study a more recent Caucasian set of predicted values for spirometry was used [12] allowing the calculation of Z-scores. After the
exclusion of non Caucasian subjects and patients with a smoking history≥ 15 pack-year for non COPD/emphysema diagnoses, 185 / 360 patients were
available for the final description.
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and Z-scores (the normative equations used are for
Caucasian subjects)
2. For the secondary objective (prevalence of NSP)
- number of patients with NSP over the number of
patients with LFT including both spirometry and
plethysmography (prevalence of NSP in our LFT,
whatever the associated disease)
- number of patients with NSP and one specific lung
disease over the number of patients with LFT
(spirometry plus plethysmography) and this specific
lung disease recorded in ICD-10 database (preva-
lence of NSP among each lung disease).
3. For the follow-up study
- patients with an NSP and at least one follow-up LFT
6 months or more after the initial assessment were
identified and included in the follow-up study.
Lung function testing was done by four experienced pul-
monary technologists. The tests included spirometry, body
plethysmography with airway resistance (Raw using sRaw
total [7]) and sometimes lung diffusion for carbon monoxide(DLCO) measurements using an automated system
(MasterScreen, Jaeger, CareFusion®, San Diego,
California: two apparatus, unchanged over the six-
years of the survey) according to the ATS/ERS task
force performed during the same visit [1,8-11]. After
raw data extraction, predicted values of Caucasians
were calculated for spirometry using Stanojevic and
colleagues reference values [12], while values for slow
VC, FEV1/slow VC and body plethysmography were
those routinely used in our testing unit [13,14].
This was an observational study in which informed con-
sent was obtained from all subjects, and the database was
declared to the French regulatory agency for computer
data (Commission Nationale de l’Informatique et des Lib-
ertés, n° 1391593 v0). Verbal consent was obtained ac-
cording to the French Law, which was confirmed by The
Institutional Review Board of the French learned society
for respiratory medicine (SPLF: CEPRO 2013–010).
Statistics
Results are expressed as mean ± SD or percentages with
95% confidence interval (CI) with the exception of MRC
Table 1 Characteristics of the 185 patients with Non
Specific Pattern of Lung Function
Characteristic 185 patients
with NSPMean ± SD (except when stated) or n
Sex, Female/Male 99/86
Age, years 57 ± 19
BMI, kg.m−2 26.9 ± 8.4
BMI≥ 30/25 to 30/< 25 kg.m−2 49/55/81
Smoking history
Never smokers, n 105
Ex-smokers, n 48
Current smokers, n 32
Pack-year, median [interquartile] 0 [0 ; 35]
MRC score, median [interquartile] 2.0 [1.0 ; 2.0]
FEV1, L 1.96 ± 0.68
FEV1,% predicted [12] 66 ± 9
FEV1, z-score - 2.51 ± 0.61
FVC, L 2.66 ± 0.82
FVC,% predicted [12] 67 ± 9
FVC, z-score - 2.58 ± 0.71
FEV1/FVC 0.77 ± 0.08
FEV1/FVC,% predicted [12] 99 ± 9
FEV1/FVC, z-score - 0.24 ± 0.98
Slow inspiratory VC, L 2.71 ± 0.79
Slow inspiratory VC,% predicted [13] 76 ± 11
FEV1 / Slow inspiratory VC 0.75 ± 0.08
FEV1 / Slow inspiratory VC, 5
th percentile [13] 0.68 ± 0.04
TLC, L 5.49 ± 1.19
TLC,% predicted [14] 96 ± 12
TLC, 5th percentile 4.66 ± 1.07
FRC, L 3.46 ± 0.92
FRC,% predicted [14] 111 ± 27
RV, L 2.68 ± 0.85
RV,% predicted [14] 131 ± 33
Rawtot, kPa.s.L
−1 0.46 ± 0.28
Rawtot,% predicted 154 ± 99
Specific Rawtot, kPa.s 1.60 ± 0.98
Specific Rawtot,% predicted 166 ± 101
VA, L (n patients with measurement)* 4.01 ± 0.90 (62)
VA/TLC (n patients with measurement) 0.75 ± 0.12 (62)
Set of predicted values are quoted in the first column.
*: among these 62 patients, 53 (85%) depicted a restrictive defect defined by
VA below the 5th percentile value of TLC minus 150 mL.
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phy and alveolar volume (VA) obtained during DLCO
measurement used the paired t test. Comparisons used
Kruskall Wallis test for continuous variables and chi-2
test for qualitative variables (see Table 1). A p value <
0.05 was deemed significant.
Results
Cross-sectional assessment
During the six-year period (2007 to 2012), the Clinical
Database Warehouse showed that 12 775 LFT (spirometry
and plethysmography) were performed and that a diagno-
sis of NSP was recorded for 841 LFT (6.6%, 95% CI: 6.2 to
7.0%, after excluding LFT with insufficient quality cri-
teria). The selection process is summarized in Figure 1.
Using ICD-10 and CCAM (for bilateral lung transplant-
ation [BLT]) codes, the prevalence of NSP (341 patients) in
each lung disease was estimated: asthma, 124/986 (12.6%,
95% CI: 10.5 to 14.6%), COPD/emphysema, 71/828 (8.6%,
95% CI: 6.7 to 10.5%), bronchiectasis, 55/431 (12.8%, 95%
CI: 9.6 to 15.9%), sarcoidosis 22/205 (10.7%, 95% CI: 6.5 to
15.0%), interstitial pneumonia 19/475 (4.0%, 95% CI: 2.2 to
5.8%), pulmonary hypertension, 33/369 (8.9%, 95% CI: 6.0
to 11.9%) and BLT for cystic fibrosis, 36/100 (36.0%,
95% CI: 26.5 to 45.5%).
The final selection of 185 Caucasian patients with
NSP allowed the description of their characteristics in
Tables 1 and 2. The results of the LFT demonstrated
that a moderate mean obstructive defect was evidenced
associated with mild air trapping. The degree of the ob-
structive defect was similar whatever the underlying dis-
ease whereas the degree of lung air trapping varied
among diseases (Table 2). Asthmatics demonstrated the
highest BMI values (Table 2), and 31/67 (46%) patients
were obese (BMI ≥30 kg.m−2).
Patients with pulmonary hypertension were classified
according to the World Health Organization Groups of
pulmonary hypertension [15] as: group 1, n = 3; group 4,
n = 2, group 5, n = 2.
Follow-up study
Among the 841 LFT evidencing a NSP, 360 patients are
described in Figure 1 while 30 additional patients were
suffering from miscellaneous diseases (see Figure 1 le-
gend). Thus the 451 remaining LFT were related to the
patients having a NSP on recurrent tests. Among the
185 patients with indisputable diagnoses, the majority
(130/185: 70% 95% CI: 64 to 77%) demonstrated a stable
pattern while 16 patients (9%, 95% CI: 5 to 13%) showed
a restrictive pattern (TLC < 5th percentile, 12 patients
with interstitial pneumonia and 4 with sarcoidosis) and
39 patients (21%, 95% CI: 15 to 27%) showed an ob-
structive pattern (FEV1/VC < 5
th percentile, 10 patients
with asthma and 29 with COPD/emphysema).Discussion
In the presence of a normal TLC, a decrease in VC, and
therefore of FEV1, is the consequence of an increase in
RV. Pathologic conditions associated with intrinsic and










Mean ± SD (except
when stated) or n N = 67 N = 55 N = 14 N = 12 N = 15 N = 7 N = 15
Sex, F/M 48/19 17/38 12/2 7/5 6/9 5/2 4/11 <0.0001
Age, years 51 ± 15 64 ± 10 60 ± 16 47 ± 15 66 ± 14 47 ± 17 28 ± 9 <0.0001
BMI, kg.m−2 30.6 ± 9.3 26.7 ± 6.2 21.1 ± 2.4 27.3 ± 5.3 28.1 ± 5.9 22.4 ± 4.6 17.7 ± 1.6 <0.0001
Smoking history <0.0001
Never smokers, n 54 0 11 9 10 6 15
Ex-smokers, n 6 31 2 3 5 1 0
Current smokers, n 7 24 1 0 0 0 0
Pack-year, median [IQ] 0 [0 – 0] 45 [36 – 59] 0 [0 – 0] 0 [0 – 4] 0 [0 – 3] 0 [0 – 0] 0 [0 – 0] <0.0001
MRC score, median [IQ] 2 [1 – 2] 2 [1 – 2] 1 [1 – 2] 2 [2 – 2] 2 [2 – 2] 2 [1 – 5] 1 [1 – 1] 0.0003
FEV1,% predicted 64 ± 7 63 ± 8 61 ± 9 67 ± 8 69 ± 8 59 ± 5 66 ± 8 0.118
FVC,% predicted 65 ± 8 65 ± 9 63 ± 9 70 ± 10 68 ± 9 63 ± 5 66 ± 9 0.239
FEV1/FVC,% predicted 97 ± 8 96 ± 7 96 ± 7 95 ± 6 99 ± 10 93 ± 5 100 ± 8 0.321
TLC,% predicted 94 ± 10 99 ± 14 96 ± 8 90 ± 7 90 ± 9 96 ± 15 93 ± 6 0.189
FRC,% predicted 102 ± 27 121 ± 26 116 ± 21 97 ± 14 96 ± 16 111 ± 35 127 ± 11 <0.0001
RV,% predicted 132 ± 33 145 ± 33 136 ± 22 119 ± 21 110 ± 25 136 ± 30 169 ± 28 <0.0001
IQ denotes interquartile.
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piratory muscle weakness, will lead to an increased RV.
Dynamic expiratory airflow obstruction could also pro-
duce an increase in RV and a decrease in FVC. However,
measuring a slow VC instead of a forced one would
avoid the rise in RV, which was not observed in our
study. Consequently, the pattern of NSP may effectively
be related to patchy collapse of small airways early in ex-
halation, and does not seem to be related to a broncho-
constrictor effect of deep inspiration [16] that would be
associated with normal slow inspiratory vital capacity.
To our best knowledge, only one study evaluated the
main lung diseases that are associated with this pattern
[4]. In the retrospective study of Hyatt and colleagues,
NSP was observed in 7702/80 929 subjects (9.5%), and a
random sample of 100 patients allowed to define the
medical conditions associated with this pattern [4]. The
authors showed that 52 patients had some degree of
airway responsiveness (positive response to broncho-
dilator or methacholine) including 26 asthmatics, 16
were suffering from chronic lung disease (including 11
with COPD and 3 with bronchiectasis), 7 were obese
only and 25 were suffering from various conditions
(prevalence ≤5% for each condition). Overall, in their
study, obesity (BMI ≥ 30 kg/m2) was very prevalent (50
subjects equally distributed between the sexes) and they
highlighted the association of NSP with obesity and
hyperresponsiveness (31%). Obesity has also been asso-
ciated with propensity of distal airway closure/hyperre-
sponsiveness [17]. We similarly observed that asthmaticpatients in our series were often obese, even if obesity
prevalence was lower in our series (26%), which may
further explain our lower prevalence of NSP. These au-
thors emphasized that some patients had no evidence of
airway disease. Restricted expansion of the thorax or
lung may have explained the NSP in most of these
subjects since the conditions were suggestive of restric-
tion despite the low normal TLC. Interestingly, some of
these conditions have also been associated with in-
creased airway responsiveness [18,19], which may have
favoured the occurrence of this NSP.
Our design had both similarities and differences.
Large databases were used in the two studies that used
body plethysmography for absolute lung volumes mea-
surements. We deliberately decided not to include all
medical conditions associated with NSP (30 patients
were excluded) because one objective was to provide
confident prevalences of the functional pattern in the
various medical conditions. The prevalence of NSP was
thus described for seven conditions associated with the
pattern, over 360 patients. Then we further selected 185
patients in order to describe the functional abnormal-
ities and to evaluate whether the severity of the pattern
varied among the seven conditions. To this end, we se-
lected only Caucasian (to use only one set of predicted
values) and non or light smokers in non COPD/emphy-
sema conditions (to exclude overlapping conditions). In
agreement with the study of Hyatt and colleagues, a
moderate impairment was evidenced (FEV1 68 ± 9% pre-
dicted in their study) [4].
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disputable diagnoses and, besides lung diseases already
associated with NSP [4], we further show that some
conditions as interstitial pneumonia, pulmonary hyper-
tension or bilateral lung transplantation are associated
with low to moderate prevalence of the syndrome.
Interestingly, in patients with bronchiolitis obliterans
syndrome after allogeneic hematopoietic stem cell
transplantation [20], Bergeron and colleagues identified
two functional phenotypes: a typical obstructive lung
defect and an atypical obstructive lung defect with a
concomitant decrease in the FEV1 and FVC with a nor-
mal total lung capacity (31% of the patients, 95% CI: 21
to 42%). Consequently, this latter prevalence is similar
to ours, and one may hypothesize that this high preva-
lence is specifically related to obliterative bronchiolitis
[21] rather than to biases related to the presence of lung
size mismatching between donor and recipient, and/or
inaccurate predicted values for donor lungs.
Before the more recent ATS/ERS Task Force recom-
mendations [1], previous international guidelines did
not formally classified this functional phenotype as an
obstructive defect, as pointed out by Stanescu [2]. In pa-
tients with established airway diseases, as COPD or
asthma, a reduction in FEV1 would be regarded by most
physicians as indicative of airway obstruction whatever
the FVC value. On the other hand, when the diagnosis
has not been established or in presence of a patient with
pulmonary hypertension, a “restrictive” pattern ob-
served after the sole spirometry may lead to misdiag-
nosis, accordingly with the low predictive value of
spirometry for lung restriction [22]. Furthermore, meas-
urement of absolute volumes by dilution technique may
lead to misdiagnosis (restrictive pattern), as suggested
by the reduction of alveolar volume as compared to
TLC, which would lead to restrictive defect diagnosis in
85% of the patients (see Table 1).
Some authors prefer to label this pattern as non spe-
cific due to the normalcy of the FEV1/VC ratio and of
the TLC [4,5]. Nevertheless, it has to be emphasized that
small airway (bronchiolar) involvement is a characteristic
or can occur in all these diseases. For instance in pul-
monary hypertension, a mild obstructive pattern is well-
described that can be associated with exercise-induced
dynamic hyperinflation [23]. Small airway disease is also
well demonstrated in interstitial pneumonias [24], sug-
gesting a mixed defect when an additional restrictive de-
fect occurs as observed in our study. The mild to
moderate lung air trapping that was evidenced in our
study together with an increase in airway resistance fur-
ther suggest distal airway obstruction. Along this line we
showed that both airway resistance and specific airway
resistance can augment in the presence of peripheral air-
way obstruction [25,26].Finally, the observed prevalence of this syndrome in
selected conditions may seem relatively high, but we
previously demonstrated that isolated hyperinflation is
not infrequent in asthmatic children (7-11%) [3]. Logic-
ally, due to this prevalence in common respiratory dis-
eases, the overall prevalence in our LFT unit (6.6%) is in
agreement with the results of Hyatt and colleagues
(9.5%) and with those of Aaron and colleagues (15%,
95% CI: 13 to 17% patients with low FVC and normal
absolute lung volumes) [22]. Unfortunately, the diagno-
ses associated with this specific functional pattern were
not described in this latter study [22].
Our study has inherent limitations due to its design.
Data extraction was based on the actual recording of
NSP by the physician in charge of the LFT report made
in the routine practice; consequently, the observed prev-
alences could have been underestimated. These preva-
lences are only indicative because some patients had
several LFT that may have facilitated the detection of
NSP, which can be a transient functional phenotype [5].
Reversibility of airway limitation was not systematically
assessed because patients are tested while taking their
usual respiratory treatment. Finally, our study was not
designed to evaluate all lung diseases associated with
NSP, since only concordant and indisputable diagnoses
were retrieved for functional description. Whether NSP
is associated with specific clinical phenotypes warrants
further studies.
Conclusion
In conclusion, NSP can be observed in asthma, COPD/
emphysema, bronchiectasis, sarcoidosis, interstitial pneu-
monias, pulmonary hypertension and after bilateral lung
transplantation. Thus, the measurement of static lung vol-
umes by body plethysmography can be helpful in presence
of FEV1 and FVC reduction, depending on previous mea-
surements, lung imaging, and clinical judgment.
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